Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Annayyaon Aug 13, 2020 1:56pm
190 Views
Post# 31404427

RE:RE:RE:News: ProMIS Neurosciences announces Q2 results

RE:RE:RE:News: ProMIS Neurosciences announces Q2 resultsCash on hand as at June 30th is $1.296 million which probably lasts two to three months, so there is not much time for them to announce the stellar news about COVID neutralizing antibodies identification success, and then they can do the PP at 30 or 40 cents rather than the 20 cents. It's hard to predict how the market will react to the great news on COVID. I wouldn't be surprised if the share price more than doubles immediately following the news as we went as high as 31 cents on 16 million volume on the previous news.
M101 wrote: I'll give them credit for collecting $1.2 million on 9.5 million warrants, lowering the warrants outstanding to 36.6 million. But that $1.2 million represents all the cash on hand as at june 30 while our reduced montly burn is still almost $600,000.  So,  do the math. 


Bullboard Posts